Menopausal Hot Flashes Market Report 2026

Menopausal Hot Flashes Market Overview

• Menopausal Hot Flashes market size has reached to $15.92 billion in 2025 • Expected to grow to $21.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Government-Led Menopausal Health Initiatives Is A Catalyst For Growth In The Menopausal Hot Flashes Market • Market Trend: Innovative Non-Hormonal Therapy Offers Relief For Moderate To Severe Hot Flashes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Menopausal Hot Flashes Market?

Menopausal hot flashes, also known as vasomotor symptoms, are common menopausal and perimenopausal symptoms that can occur as an intense burst of heat, sweating, and heated skin in women. Hot flashes can be irritating and unpleasant, causing discomfort, anxiety, and sleep disruption. The main types of treatment for menopausal hot flashes are hormonal treatment, non-hormonal treatment, and alternative treatment. Hormonal treatment refers to therapy for a woman during her menopause period when her body stops producing estrogen, and the therapy involves taking a medicine that contains female hormones to replace estrogen. The various pipeline analysis includes phase iii drugs and phase I and II drugs, which are delivered through various distribution channels, including retail pharmacies, online pharmacies, and hospital pharmacies. The various applications include 51-55-year-old women, 46-50-year-old women, and 40-45-year-old women.

What Is The Menopausal Hot Flashes Market Growth Forecast?

The menopausal hot flashes market size is expected to see strong growth in the next few years. It will grow to $21.68 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising demand for safer non-hormonal therapies, growth in menopause-focused healthcare programs, increasing focus on women’s health research, expansion of online and digital health consultations, growing acceptance of alternative treatment methods. Major trends in the forecast period include rising preference for non-hormonal treatment options, growing awareness and diagnosis of menopausal symptoms, increasing adoption of alternative and lifestyle-based therapies, expansion of personalized menopause management approaches, higher demand for long-term symptom management solutions.

Global Menopausal Hot Flashes Market Segmentation

1) By Type: Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment 2) By Pipeline Analysis: Phase III Drugs, Phase I And II Drugs 3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospital Pharmacies 4) By Application: 51-55 Year Old Woman, 46-50 Year Old Woman, 40-45 Year Old Woman Subsegments: 1) By Hormonal Treatment: Estrogen Therapy, Combined Hormonal Therapy 2) By Non-Hormonal Treatment: Selective Serotonin Reuptake Inhibitors, Gabapentinoids, Clonidine 3) By Alternative Treatment: Herbal Supplements, Acupuncture, Lifestyle Modifications

What Is The Driver Of The Menopausal Hot Flashes Market?

The government’s initiatives for women’s health in menopause are expected to propel the growth of the menopausal hot flashes market going forward. Government initiatives for menopausal health refer to dedicated programs, funding, and policy actions aimed at improving care, supporting research, and enhancing access to services for women experiencing menopause-related symptoms. These initiatives are increasing as governments recognize the need for better education, early diagnosis, and effective treatment options to support women’s health during the menopausal transition. The menopausal hot flashes market benefits from such initiatives by strengthening research efforts, accelerating innovation, and improving access to evidence-based treatments for symptom relief. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government allocated 0.0403 billion over four years (2022–2023 to 2025–2026) to establish up to 16 new programs supporting women with severe menopausal symptoms. Therefore, the government’s initiatives for women’s health in menopause are driving the growth of the menopausal hot flashes industry.

Key Players In The Global Menopausal Hot Flashes Market

Major companies operating in the menopausal hot flashes market are Pfizer Inc., Johnson & Johnson, The Procter & Gamble Company, Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Gedeon Richter Plc, Lupin Limited, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Ligand Pharmaceuticals Inc., Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex Ltd., Ascend Therapeutics Inc., EndoCeutics Inc., Sermonix Pharmaceuticals LLC, Ralington pharma LLP

Global Menopausal Hot Flashes Market Trends and Insights

Major companies operating in the global menopausal hot flashes market are focusing on developing innovative therapies, such as non-hormonal neurokinin-3 (NK3) receptor antagonists, to provide safer and more effective treatment options for women who cannot or prefer not to use hormone therapy. Non-hormonal NK3 receptor antagonists are targeted medications that work by blocking neurokinin-3 receptors in the brain’s thermoregulatory center to reduce the frequency and severity of vasomotor symptoms, including moderate to severe hot flashes. For instance, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company has received the approval Food and Drug Administration (FDA) Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. It is world’s first non-hormonal NK3 receptor antagonist specifically developed for menopausal hot flashes. Veozah offers a novel non-hormonal mechanism of action, once-daily oral dosing, and clinically demonstrated reductions in both frequency and intensity of vasomotor symptoms, representing a major advancement for women seeking non-hormonal menopause-related symptom relief.

What Are Latest Mergers And Acquisitions In The Menopausal Hot Flashes Market?

In November 2023, Pharmavite LLC, a US-based nutrition‑powered wellness company, acquired Bonafide Health for $42 million. With this acquisition, Pharmavite aims to strengthen and expand its women’s health business by integrating Bonafide Health’s clinically validated menopause and midlife wellness solutions into its existing portfolio. Bonafide Health LLC is a US-based women’s health company specializing in developing and providing non-hormonal, plant-based supplements specifically designed to relieve menopausal hot flashes.

Regional Outlook

North America was the largest region in the Menopausal Hot Flashes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Menopausal Hot Flashes Market?

The menopausal hot flashes market consists of revenues earned by entities by providing estrogen therapy, and menopause hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal hot flashes market also includes sales of venlafaxine, paroxetine, and escitalopram. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Menopausal Hot Flashes Market Report 2026?

The menopausal hot flashes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the menopausal hot flashes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.